Novozymes A/S

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novonesis A/S engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.

Novozymes A/S (NVZMF) Q1 2023 Earnings Call Transcript.

Novozymes A/S (NVZMF) Q1 2023 Earnings Call Transcript

After the first quarter of 2023, Novozymes delivers stronger results than expected with 5% organic sales growth. The company confirms the 2023 outlook of 4-7% which is expected to be driven by pricing and volume growth.

Novozymes delivers stronger than expected Q1 results

Ambev

Bayer AG

Anheuser-Busch InBev

Experian PLC

Roche Holding AG

Toronto-Dominion Bank

Taiwan Semiconductor Manufacturing

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

International Wide-Moat Stocks On Sale - The April 2023 Heat Map

The proposed combination of Novozymes and Chr. Hansen has now been approved by each company's respective shareholders, and with strong support from the shareholders the two biosolutions companies are now one step closer to uniting. The new company is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large.

Novozymes' and Chr. Hansen's shareholders approve combination to create a leading global biosolutions partner

Resolutions from Novozymes A/S' Extraordinary Shareholders' Meeting on 30 March 2023

Combination between Novozymes and Chr. Hansen approved by the Novozymes shareholders

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL.

Update on the combination of Novozymes and Chr. Hansen: U.S. antitrust regulation waiting period has expired, supporting the path to completion

Please read the full announcement in the attached PDF

Publication of exemption document in relation to the proposed combination of Novozymes and Chr. Hansen, confirmation of outlook for 2023 and proposed candidates to the Board of Directors of the combined company

Reckitt Benckiser Group PLC

Sanofi

Tencent Holdings Limited

International Wide-Moat Stocks On Sale - The March 2023 Heat Map

Resolutions from Novozymes A/S' Annual Shareholders' Meeting 2023. Please read the full announcement in PDF.

Resolutions from Novozymes A/S' Annual Shareholders' Meeting 2023

Westlake Chemical Partners LP

WLKP vs. NVZMY: Which Stock Is the Better Value Option?

WLKP vs. NVZMY: Which Stock Should Value Investors Buy Now?

International Wide-Moat Stocks On Sale - The February 2023 Heat Map

Invitation to Novozymes' annual shareholders' meeting 2023

Novozymes A/S (OTCPK:NVZMF) Q4 2022 Earnings Conference Call January 26, 2023 3:00 AM ET Company Participants Tobias Bjorklund - Head of Investor Relations Ester Baiget - President and CEO Lars Green - Executive Vice President and CFO Tina Sejersgard Fano - Executive Vice President, Agriculture & Industrial Biosolutions Amy Byrick - Executive Vice President, Strategy & Business Transformation Anders Lund - Executive Vice President, Consumer Biosolutions Claus Fuglsang - CSO and EVP-Research & Development Conference Call Participants Alexander Jones - BofA Lars Topholm - Carnegie Investment Bank Chetan Udeshi - JPMorgan Soren Samsoe - SEB Andre Thormann - Danske Bank Nicola Tang - BNP Paribas Tobias Bjorklund Thank you, operator, and welcome, everyone, to Novozymes Full-Year 2022 Conference Call. My name is Tobias Bjorklund, and I'm the Head of Investor Relations here at Novozymes.

Novozymes A/S (NVZMF) Q4 2022 Earnings Call Transcript

Novozymes is delivering strong growth and earnings in a volatile market environment with 9% organic sales growth in 2022. This marks the highest organic sales growth in more than a decade, and Novozymes is confident about the 2023 outlook of 4-7%.

Novozymes delivers historically strong full-year results

Novozymes and Chr. Hansen receive binding tax ruling that the proposed merger can be completed as a tax-exempt merger

Novozymes is a Danish company that produces industrial enzymes, often used to replace chemicals in products and industrial processes. The company's products have a wide range of applications in household care, food and beverage, bio-energy, agriculture, feed, and even pharmaceutical products.

Novozymes: Wonderful Company, Almost Reasonable Price

CLERMONT-FERRAND, France--( BUSINESS WIRE )--Regulatory News:

Carbios and Novozymes Strengthen Collaboration With Long-Term Exclusive Strategic Partnership to Secure Worldwide Leadership in Biorecycling of PET

James Hardie Industries

MercadoLibre

Royal Bank of Canada

International Wide-Moat Stocks On Sale - The January 2023 Heat Map

Novozymes and Chr. Hansen agree deal to merge

Today, Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. The combination is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large.

Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner

Novozymes has renewed its climate targets and by 2030 will reduce its absolute CO2 emissions across its operation by 75% and reduce its absolute CO2 emissions from its supply chain by 35%. By 2050, Novozymes will reach net-zero.

As one of the first companies in the world, Novozymes has had its net-zero target validated by the Science Based Targets initiative

COPENHAGEN, Denmark – November 10, 2022. Novozymes, the world leader in biological solutions, and LinusBio (Linus Biotechnology Inc.), a leader in precision exposome sequencing, today announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial. The project will apply LinusBio's environmental biodynamics platform, enabling detailed temporal mapping of harmful compound exposure, to a clinical trial of probiotics sponsored by Novozymes' human health unit, Novozymes OneHealth. The clinical trial will assess exposure to heavy metals, such as lead, and a broad range of environmental pollutants, and is part of a larger clinical program from Novozymes OneHealth.

Novozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth

Novozymes A/S (OTCPK:NVZMF) Q3 2022 Earnings Conference Call November 3, 2022 4:00 AM ET Company Participants Tobias Cornelius Bjorklund - Head-Investor Relations Ester Baiget - Chief Executive Officer Lars Green - Chief Financial Officer Tina Fanoe - Executive Vice President-Agriculture & Industrial Biosolutions Amy Byrick - Executive Vice President-Strategy & Business Transformation Anders Lund - Executive Vice President-Consumer Biosolutions Claus Fuglsang - CSO and EVP-Research & Development Conference Call Participants Gunther Zechmann - Bernstein Søren Samsøe - SEB Alex Jones - Bank of America Sam Perry - Credit Suisse Chetan Udeshi - JPMorgan Sebastian Bray - Berenberg Lars Topholm - Carnegie Operator Welcome to the Novozymes conference call regarding the results for the first nine months of 2022. [Operator Instructions] Today, I am pleased to announce, Tobias Cornelius Bjorklund.

Novozymes A/S (NVZMF) Q3 2022 Earnings Call Transcript

Novozymes delivered 9% organic sales growth in the first nine months of 2022 and 6% organic sales growth in the third quarter. As announced on October 7, the full-year organic sales growth outlook was raised from 6-8 % to now 8-9 % following a strong performance in the first nine months of the year, and expectedly, continued strong Q4 momentum.

Novozymes confirms upgraded guidance by strong start to Q4

News for Novozymes A/S Stock (NVZMY)